WHEREAS:Registration Rights Agreement • December 20th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec • Illinois
This distribution agreement (the "Agreement") is made and entered into by and between: L. MOLTENI & C. dei F.lli Alitti Societa di Esercizio S.p.A., a company existing and organized under the laws of Italy, with registered office at Strada Statale 67...Distribution Agreement • May 21st, 2007 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research
ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF WebxAgreement and Plan of Reorganization • April 11th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec • Nevada
EXHIBIT 10.10 FIRST AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT THIS FIRST AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT (the "Amendment"), dated as of January 3, 2001, by and between STEROIDOGENESIS INHIBITORS INTERNATIONAL, INC. (D/B/A SAMARITAN...Common Stock Purchase Agreement • January 17th, 2001 • Steroidogenesis Inhibitors International Inc • Services-business services, nec
EXHIBIT 10.8 EMPLOYMENT AGREEMENT THIS AGREEMENT ("Agreement") is made by and between SAMARITAN PHARMACEUTICALS, INC. a Nevada Corporation ("Company") and Eugene Boyle, an individual ("Executive"), as of January 1, 2001 (the "Effective Date"), who...Employment Agreement • August 14th, 2002 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Nevada
Exhibit 10.7 This assignment is made by Dr. Alfred T. Sapse, M.D. residing at 3525 Leor Court, Las Vegas, Nevada 89121, ("ASSIGNOR") to Steroidogenesis Inhibitors International, a corporation organized under the laws of the State of Nevada and having...Assignment Agreement • April 12th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec
This assignment is made by Dr. Alfred T. Sapse, M.D. residing at 3525 Leor Court, Las Vegas, Nevada 89121, ("ASSIGNOR") to Steroidogenesis Inhibitors International, a corporation organized under the laws of the State of Nevada and having an office at 101 Convention Center Drive, Suite 310, Las Vegas, Nevada 89109 ("ASSIGNEE").
WHEREAS:Registration Rights Agreement • May 13th, 2005 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Nevada
EXHIBIT 10.7 EMPLOYMENT AGREEMENT THIS AGREEMENT ("Agreement") is made by and between SAMARITAN PHARMACEUTICALS, INC. a Nevada Corporation ("Company") and Doug Bessert, an individual ("Executive"), as of April 1, 2001 (the "Effective Date"), who agree...Employment Agreement • August 15th, 2002 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Nevada
CONSULTING AGREEMENT This Agreement is effective as of the 17th day of December, 1998, by and between Steroidogenesis Inhibitors International, a Nevada corporation (the "Company"), and The Augustine Equity Fund, a Canadian corporation (the...Consulting Agreement • February 28th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec • Nevada
RECITALSLicense and Distribution Agreement • May 21st, 2007 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Pennsylvania
AGREEMENTResearch and Development • March 27th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec • California
LICENSE AGREEMENTLicense Agreement • February 28th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec • Nevada
SCHEDULE B EXCLUSIVE LICENSING AGREEMENTExclusive Licensing Agreement • April 11th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec
WITNESSTH:Common Stock Purchase Agreement • December 15th, 2005 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Nevada
EXHIBIT 10.6Employment Agreement • August 16th, 2004 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Nevada
RECITALSConsulting Agreement • February 28th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec
Exhibit 99 TO: STEREOIDOGENESIS INHIBITORS INTERNATIONAL, INC. ("STGI") This document is to confirm my agreement as a commitment for the continued funding of monies to STGI up to the $2,000,000 I am committed to. The agreement is as follows: 1. I will...Subscription Agreement • April 12th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec
LEXXUS CAPITAL 405 Lexington Avenue, 47th Floor New York, New York 10174 212-972-3350Consulting Agreement • February 24th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec • New York
Exhibit 10.7 This assignment is made by Dr. Alfred T. Sapse, M.D. residing at 3525 Leor Court, Las Vegas, Nevada 89121, ("ASSIGNOR") to Steroidogenesis Inhibitors International, a corporation organized under the laws of the State of Nevada and having...Ip Transfer Agreement • February 24th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec
This assignment is made by Dr. Alfred T. Sapse, M.D. residing at 3525 Leor Court, Las Vegas, Nevada 89121, ("ASSIGNOR") to Steroidogenesis Inhibitors International, a corporation organized under the laws of the State of Nevada and having an office at 101 Convention Center Drive, Suite 310, Las Vegas, Nevada 89109 ("ASSIGNEE").
EXHIBIT 10.10 RESEARCH COLLABORATION AND LICENSING AGREEMENT BETWEEN GEORGETOWN UNIVERSITY AND SAMARITAN PHARMACEUTICALS, INC.Research Collaboration and Licensing Agreement • July 31st, 2003 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • District of Columbia
DATED September 6th 2007 - and – EXCLUSIVE DISTRIBUTION AGREEMENTExclusive Distribution Agreement • April 14th, 2008 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • England
as the Supplier - and - PHARMAPLAZ LIMITED as the Buyer - and - SAMARITAN IRELAND PHARMACEUTICALS LIMITED as the Finished Product License Holder - and - SAMARITAN PHARMACEUTICALS INC as the Parent Company of the Finished Product License Holder SUPPLY...Supply Agreement • September 27th, 2005 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research
WHEREAS:Common Stock Purchase Agreement • May 13th, 2005 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Nevada
RESEARCH COLLABORATION AND LICENSING AGREEMENT AMONG The RESEARCH INSTITUTE of MCGILL UNIVERSITY HEALTH CENTER AND SAMARITAN PHARMACEUTICALS, INC. AND SAMARITAN THERAPEUTICSResearch Collaboration and Licensing Agreement • July 25th, 2007 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Quebec
This RESEARCH COLLABORATION AND LICENSING AGREEMENT (“Agreement”), is entered into as of , by and between the Research Institute of McGill University Health Center (“RI-MUHC”), a research and educational institution located at and Samaritan Pharmaceuticals, Inc. (“Samaritan”), a for-profit corporation organized under the laws of the State of Nevada, with its principal place of business at and Samaritan Therapeutics (“Therapeutics”), a Canadian corporation located at (Collectively “Parties”).
WHEREAS:Common Stock Purchase Agreement • April 25th, 2003 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Nevada
SAMARITAN PHARMACEUTICALS IRELAND INC. LIMITED PATENT AND TRADEMARK LICENSE AGREEMENTPatent and Trademark License Agreement • November 19th, 2008 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of the following Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)and Trademark(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), Appendix G (Royalty Payment Options), and Appendix H (Model Use Sublicense). The Parties to this Agreement are:
Exhibit 10.17 SAMARITAN PHARMACEUTICALS, INC. DIRECTOR/OFFICER'S INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is made as of ______________ by and between Samaritan Pharmaceuticals, Inc., a Nevada corporation (the "Company"),...Indemnification Agreement • August 14th, 2006 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Nevada
COOPERATIVE LOCK UP AGREEMENTCooperative Lock Up Agreement • June 12th, 2007 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Nevada
This cooperative lock up agreement (the “Lock Up Agreement”) is made this 7th day of June 2007 by and among Samaritan Pharmaceuticals Inc. (the “Company”) and Doug Bessert and KD1, Inc. (the “Participants”) with respect to shares of common stock of the Company (the “Shares”). The Participants own shares of the company and desire to enter into this agreement among themselves to implement certain selling restrictions or lock up arrangements related to their Shares on the terms and conditions herein contained.
Samaritan Pharmaceuticals, Inc. and Samaritan Pharmaceuticals Ireland Ltd., agreement with Pharmaplaz Ltd., Research, Development and Commercialization Collaboration AgreementResearch, Development and Commercialization Collaboration Agreement • March 28th, 2007 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research
This Agreement (“Licensing Collaboration”) between Samaritan Pharmaceuticals, Inc. and Samaritan Pharmaceuticals Ireland Ltd. (“Samaritan”) with Pharmaplaz Ltd. (“Pharmaplaz”) is made and entered into as of this 9th day of March, 2007. Samaritan and Pharmaplaz have entered into this agreement for the purpose of allocating between the parties certain rights relating to an SP-01A project to be carried out by Pharmaplaz and Samaritan (hereinafter referred to as the “PARTIES”).
EXHIBIT 10.10 EMPLOYMENT AGREEMENT TRUST UNDER SAMARITAN PHARMACEUTICALS, INC. DEFERRED COMPENSATION PLAN SAMARITAN PHARMACEUTICALS, INC. ("Company") and ______________("Trustee") agree: WHEREAS, Company has adopted a Deferred Compensation Plan...Employment Agreement • August 14th, 2002 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research • Nevada
Exhibit 10.18 Samaritan Pharmaceuticals, Inc. and Samaritan Pharmaceuticals Ireland Ltd., agreement with Pharmaplaz Ltd., Research, Development and Commercialization Collaboration Agreement Supplement This Supplement Agreement ("Licensing...Licensing Collaboration Agreement • May 21st, 2007 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research
FIRST AMENDMENT TO THE AGREEMENT BETWEEN SAMARITAN PHARMACEUTICALS, INC. AND SAMARITAN PHARMACEUTICALS IRELAND LTD., AGREEMENT WITH PHARMAPLAZ LTD., RESEARCH, DEVELOPMENT AND COMMERCIALIZATION COLLABORATION AGREEMENTResearch, Development and Commercialization Collaboration Agreement • September 21st, 2007 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research
This First Amendment to Agreement is entered into by and between Samaritan Pharmaceuticals, Inc. and Samaritan Pharmaceuticals Ireland Ltd (“Samaritan”) with Pharmaplaz Ltd. (“Pharmaplaz”), dated March 9, 2007. In consideration of the mutual undertakings and covenants hereinafter set forth, the PARTIES agree as follows:
LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • April 14th, 2008 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research
This Agreement is made as of the 23rd of November 2007 by ABIOGEN PHARMA SPA, a corporation organized and existing under the Laws of Italy and having its principal offices at Via Meucci 36, 56014 Ospedaletto Pisa Italy, represented by the Managing Director, Dr. Massimo Di Martino (hereinafter called "ABIOGEN"), and
RECITALS:Warrant Agency Agreement • April 11th, 2000 • Steroidogenesis Inhibitors International Inc • Services-business services, nec • Nevada
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • April 14th, 2008 • Samaritan Pharmaceuticals Inc • Services-commercial physical & biological research
